The ARAUCARIA project: Grid-Based Quantitative Spectroscopic Study of Massive Blue Stars in NGC55

The quantitative study of the physical properties and chemical abundances of large samples of massive blue stars at different metallicities is a powerful tool to understand the nature and evolution of these objects. Their analysis beyond the Milky Way is challenging, nonetheless it is doable and the best way to investigate their behavior in different environments. Fulfilling this task in an objective way requires the implementation of automatic analysis techniques that can perform the analyses systematically, minimizing at the same time any possible bias. As part of the ARAUCARIA project we carry out the first quantitative spectroscopic analysis of a sample of 12 B-type supergiants in the galaxy NGC55 at 1.94 Mpc away. By applying the methodology developed in this work, we derive their stellar parameters, chemical abundances and provide a characterization of the present-day metallicity of their host galaxy. Based on the characteristics of the stellar atmosphere/line formation code FASTWIND, we designed and created a grid of models for the analysis of massive blue supergiant stars. Along with this new grid, we implemented a spectral analysis algorithm. Both tools were specially developed to perform fully consistent quantitative spectroscopic analyses of low spectral resolution of B-type supergiants in a fast and objective way. We present the main characteristics of our FASTWIND model grid and perform a number of tests to investigate the reliability of our methodology. The automatic tool is applied afterward to a sample of 12 B-type supergiant stars in NGC55, deriving the stellar parameters and abundances. The results indicate that our stars are part of a young population evolving towards a red supergiant phase. The derived chemical composition hints to an average metallicity similar to the one of the Large Magellanic Cloud, with no indication of a spatial trend across the galaxy.Comment: 19 pages, 12 figures and 9 tables. Accpeted for publication in A&

Size Dependence of Current-Voltage Properties in Coulomb Blockade Networks

We theoretically investigate the current-voltage (I-V) property of two-dimensional Coulomb blockade (CB) arrays by conducting Monte Carlo simulations. The I-V property can be divided into three regions and we report the dependence of the aspect ratio delta (namely, the lateral size N_{y} over the longitudinal one N_{x}). We show that the average CB threshold obeys a power-law decay as a function of delta. Its exponent gamma corresponds to a sensitivity of the threshold depending on delta, and is inversely proportional to N_{x} (i.e., delta at fixed N_{y}). Further, the power-law exponent zeta, characterizing the nonlinearity of the I-V property in the intermediate region, logarithmically increases as delta increases. Our simulations describe the experimental result zeta=2.25 obtained by Parthasarathy et al. [Phys. Rev. Lett. 87 (2001) 186807]. In addition, the asymptotic I-V property of one-dimensional arrays obtained by Bascones et al. [Phys. Rev. B. 77 (2008) 245422] is applied to two-dimensional arrays. The asymptotic equation converges to the Ohm's law at the large voltage limit, and the combined tunneling-resistance is inversely proportional to delta. The extended asymptotic equation with the first-order perturbation well describes the experimental result obtained by Kurdak et al. [Phys. Rev. B 57 (1998) R6842]. Based on our asymptotic equation, we can estimate physical values that it is hard to obtain experimentally.Comment: 21 pages, 10 figures, accepted for publication in Journal of the Physical Society of Japa

Mixed cryoglobulinemia

Mixed cryoglobulinemia (MC), type II and type III, refers to the presence of circulating cryoprecipitable immune complexes in the serum and manifests clinically by a classical triad of purpura, weakness and arthralgias. It is considered to be a rare disorder, but its true prevalence remains unknown. The disease is more common in Southern Europe than in Northern Europe or Northern America. The prevalence of 'essential' MC is reported as approximately 1:100,000 (with a female-to-male ratio 3:1), but this term is now used to refer to a minority of MC patients only. MC is characterized by variable organ involvement including skin lesions (orthostatic purpura, ulcers), chronic hepatitis, membranoproliferative glomerulonephritis, peripheral neuropathy, diffuse vasculitis, and, less frequently, interstitial lung involvement and endocrine disorders. Some patients may develop lymphatic and hepatic malignancies, usually as a late complication. MC may be associated with numerous infectious or immunological diseases. When isolated, MC may represent a distinct disease, the so-called 'essential' MC. The etiopathogenesis of MC is not completely understood. Hepatitis C virus (HCV) infection is suggested to play a causative role, with the contribution of genetic and/or environmental factors. Moreover, MC may be associated with other infectious agents or immunological disorders, such as human immunodeficiency virus (HIV) infection or primary Sjögren's syndrome. Diagnosis is based on clinical and laboratory findings. Circulating mixed cryoglobulins, low C4 levels and orthostatic skin purpura are the hallmarks of the disease. Leukocytoclastic vasculitis involving medium- and, more often, small-sized blood vessels is the typical pathological finding, easily detectable by means of skin biopsy of recent vasculitic lesions. Differential diagnoses include a wide range of systemic, infectious and neoplastic disorders, mainly autoimmune hepatitis, Sjögren's syndrome, polyarthritis, and B-cell lymphomas. The first-line treatment of MC should focus on eradication of HCV by combined interferon-ribavirin treatment. Pathogenetic treatments (immunosuppressors, corticosteroids, and/or plasmapheresis) should be tailored to each patient according to the progression and severity of the clinical manifestations. Long-term monitoring is recommended in all MC patients to assure timely diagnosis and treatment of the life-threatening complications. The overall prognosis is poorer in patients with renal disease, liver failure, lymphoproliferative disease and malignancies

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

BACKGROUND Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. METHODS In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpoints for the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. FINDINGS Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). INTERPRETATION Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes. FUNDING Intercept Pharmaceuticals